Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Phan, Quynh-An
EPICS-III, NCT05133336: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Active, not recruiting	2/3	186	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	05/25	05/25
VANTAGE, NCT05050136: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis	Recruiting	2	180	Europe, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc.	Primary Biliary Cholangitis, PBC	12/25	12/25
VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)	Recruiting	2	200	Europe, Canada, US, RoW	Volixibat, SHP626, Placebo	Mirum Pharmaceuticals, Inc.	Primary Sclerosing Cholangitis	09/25	12/25